D. Goodkin

E. Waubant, D. Goodkin, L. Gee, 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Clinical and demographic predictors of cognitive performance in multiple sclerosis. Do diagnostic type, disease duration, and disability matter?

D. Goodkin, W. Beatty, W W Beatty, 1990, Archives of neurology.

Pharmacotherapy of multiple sclerosis: current status.

R. Ransohoff, D. Goodkin, R. Rudick, 1992, Cleveland Clinic journal of medicine.

Interferon beta therapy for multiple sclerosis.

D. Goodkin, 1998, Lancet.

Cognitive disturbances in patients with relapsing remitting multiple sclerosis.

P. A. Beatty, D. Goodkin, W. Beatty, 1989, Archives of neurology.

Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination.

D. Goodkin, W. Beatty, 1990, Archives of neurology.

Immunotherapy for Multiple Sclerosis

D. Goodkin, Dr R. Philip Kinkel, Dr R. Philip Kinkel, 1994, Clinical Immunotherapeutics.

Drugs Used to Treat Spasticity

D. Goodkin, M. Kita, 2000, Drugs.

Treatment of Multiple Sclerosis with Methotrexate

J. Fischer, D. Goodkin, 1996 .

Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis

S. Medendorp, J. Fischer, R. Rudick, 1995, Annals of neurology.

Treatment of Multiple Sclerosis

M. Swash, R. Rudick, D. Goodkin, 1992, Clinical Medicine and the Nervous System.

Linkage analysis of candidate myelin genes in familial multiple sclerosis

J. Haines, M. Pericak-Vance, G. Gyapay, 1999, Neurogenetics.

Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group.

J. Haines, M. Pericak-Vance, E. Martin, 1998, Human molecular genetics.

A meta-analysis of genomic screens in multiple sclerosis. The Transatlantic Multiple Sclerosis Genetics Cooperative.

J. Haines, M. Pericak-Vance, N. Risch, 2001, Multiple sclerosis.

Diagnostic criteria for multiple sclerosis research involving multiply affected families.

R. Rudick, R. Ransohoff, D. Goodkin, 1991, Archives of neurology.

Moderating Effects of Coping on the Relationship Between Stress and the Development of New Brain Lesions in Multiple Sclerosis

Michael Weiner, David C Mohr, M. Weiner, 2002, Psychosomatic medicine.

Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis.

D. Mohr, S. Hauser, D. Goodkin, 2001, Archives of neurology.

CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis

J. Haines, M. Pericak-Vance, E. Vittinghoff, 2000, Immunogenetics.

Linkage and association analysis of chromosome 19q13 in multiple sclerosis

J. Haines, M. Pericak-Vance, E. Martin, 2001, Neurogenetics.

Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS

E. Waubant, R. Rudick, D. Goodkin, 2001, Journal of Neuroimmunology.

The psychosocial impact of multiple sclerosis: exploring the patient's perspective.

D. Mohr, D. Goodkin, D E Goodkin, 1999, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis

D. Goodkin, D E Goodkin, D C Mohr, 1999, Multiple sclerosis.

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment

D. Mohr, D. Goodkin, D E Goodkin, 1996, Multiple sclerosis.

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.

D. Mohr, R. Rudick, D. Goodkin, 1997, Archives of neurology.

Interferon beta treatment for multiple sclerosis: persisting questions

D. Goodkin, 1996, Multiple sclerosis.

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

D. Pelletier, D. Goodkin, S. Zamvil, 2004, Multiple sclerosis.

Serum cobalamin deficiency is uncommon in multiple sclerosis.

D. Goodkin, M. Secic, R. Green, 1994, Archives of neurology.

Neuropsychological effects of interferon β‐1a in relapsing multiple sclerosis

J. Grafman, C. Granger, M. Lezak, 2000 .

Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests.

D. Goodkin, D E Goodkin, D Hertsgaard, 1988, Archives of physical medicine and rehabilitation.

T2 relaxation time histograms in multiple sclerosis.

S. Nelson, D. Grenier, D. Pelletier, 2002, Magnetic resonance imaging.

Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject

D. Goodkin, W. Likosky, David C. Mohr, 2001, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Access to Semantic Memory in Parkinson's Disease and Multiple Sclerosis

D. Goodkin, W. Beatty, N. Monson, 1989, Journal of geriatric psychiatry and neurology.

Implicit Learning in Patients with Chronic Progressive Multiple Sclerosis

Nancy L. Monson, P. A. Beatty, D. Goodkin, 1990 .

Interferon β therapy for multiple sclerosis

D. Goodkin, 1998, The Lancet.

Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis.

D. Mohr, D. Goodkin, P. Dwyer, 2000, Journal of consulting and clinical psychology.

3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain.

S. Nelson, D. Grenier, D. Pelletier, 2002, Magnetic resonance imaging.

Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis.

D. Mohr, D. Goodkin, A. Bostrom, 2001, Journal of consulting and clinical psychology.

Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la

D. Goodkin, D E Goodkin, D C Mohr, 1998, Multiple sclerosis.

A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis

S J Nelson, P Bacchetti, S. Nelson, 2000, Multiple sclerosis.

The Natural History of Multiple Sclerosis

D. Goodkin, 1992 .

Treatment of Depression in Multiple Sclerosis: Review and Meta‐analysis

D. Mohr, D. Goodkin, 2006 .

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials

J. Simon, R. Priore, L. Jacobs, 1998, Multiple sclerosis.

Depression, coping and level of neurological impairment in multiple sclerosis

D. Goodkin, J. Van Der Wende, D. Mohr, 1997, Multiple sclerosis.

Seasonal variation of multiple sclerosis exacerbations in North Dakota.

D. Goodkin, Doris Hertsgaard, 1989, Archives of neurology.

Overview of azathioprine treatment in multiple sclerosis

R. Hughes, K. McPherson, A. Ghezzi, 1991, The Lancet.

Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis

R. Herndon, E. Waubant, R. Rudick, 1999 .

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis

R. Herndon, R. Rudick, F. Munschauer, 2005, Multiple sclerosis.

1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS

M W Weiner, B J Soher, A A Maudsley, 2000, Multiple sclerosis.

Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis.

D. Mohr, S. Nelson, T. Luks, 2003, Journal of consulting and clinical psychology.

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.

P Bacchetti, E. Waubant, D. Goodkin, 1999, Neurology.

IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS

E. Waubant, R. Lindberg, D. Goodkin, 2003, Neurology.

Identification of Beck Depression Inventory Items Related to Multiple Sclerosis

D. Mohr, D. Goodkin, L. Beutler, 1997, Journal of Behavioral Medicine.

Relationships among illness uncertainty, stress, coping, and emotional well-being at entry into a clinical drug trial.

R. Rudick, D. Goodkin, N. Wineman, 1996, Applied nursing research : ANR.

Low-dose oral methotrexate in chronic progressive multiple sclerosis

S. Medendorp, R. Rudick, D. Goodkin, 1996, Neurology.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1

C. Granger, R. Herndon, R. Kinkel, 1999, Journal of Neuroimmunology.

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-lb in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis

D. Goodkin, D. Touchette, Tracy L. Durgin, 2003 .

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.

D. Goodkin, D. Touchette, Tracy L. Durgin, 2003, Clinical therapeutics.

Assessing Efficacy in Clinical Trials of Treatments for Multiple Sclerosis

E. Waubant, D. Goodkin, 1996 .

MS clinical trial design for the future

D. Goodkin, 1996, Multiple sclerosis.

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.

D. Mohr, D. Goodkin, P. Dwyer, 1999, Archives of neurology.

EDSS reliability

D. Goodkin, D E Goodkin, 1991, Neurology.

Affective judgments by patients with Parkinson’s disease or chronic progressive multiple sclerosis

P. A. Beatty, D. Goodkin, W. Beatty, 1989 .

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.

E. Waubant, D. Goodkin, L. Gee, 1999, Archives of neurology.

Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.

R. Rudick, T. Greene, D. Goodkin, 1992, The Online journal of current clinical trials.

Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials.

R. Rudick, D. Goodkin, Doris Hertsgaard, 1989, Archives of neurology.

D. Goodkin, 2003, Multiple sclerosis.

Experimental therapies for multiple sclerosis: current status.

R. Rudick, R. Ransohoff, D. Goodkin, 1992, Cleveland Clinic journal of medicine.

How should we proceed with disease-modifying treatments for multiple sclerosis?

E. Waubant, D. Goodkin, P. Andersson, 1997, The Lancet.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

R. Herndon, R. Rudick, J. Simon, 1998, Neurology.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

R. P. Kinkel, D. L. Cookfair, R. Herndon, 1997, Neurology.

The Natural History of Multiple Sclerosis

D. Goodkin, 1992 .

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

J. Grafman, C. Granger, M. Lezak, 2000, Annals of neurology.

A longitudinal study of T1 hypointense lesions in relapsing MS

J H Simon, R. Herndon, R. Kinkel, 2000, Neurology.

A longitudinal study of brain atrophy in relapsing multiple sclerosis

R. Herndon, R. Kinkel, J. Fischer, 1999, Neurology.

A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis

R. Kinkel, B. Weinstock-Guttman, D. Goodkin, 1998, Neurology.

Ethical considerations raised by the approval of interferon beta‐1b for the treatment of multiple sclerosis

D. Goodkin, G. Kanoti, D. Goodkin, 1994, Neurology.

Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI)

R. Paul, D. Goodkin, D. Goodkin, 1995, Neurology.